Caption Management’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.35M Buy
105,000
+60,000
+133% +$764K 0.01% 932
2025
Q4
$405K Sell
45,000
-75,000
-63% -$1.03M ﹤0.01% 1274
2025
Q3
$2.07M Buy
120,000
+85,000
+243% +$1.05M 0.02% 833
2025
Q2
$328K Hold
35,000
﹤0.01% 1196
2025
Q1
$249K Sell
35,000
-25,000
-42% -$253K ﹤0.01% 1232
2024
Q4
$700K Sell
60,000
-32,100
-35% -$501K 0.01% 1000
2024
Q3
$1.89M Buy
92,100
+55,900
+154% +$1.29M 0.03% 580
2024
Q2
$810K Hold
36,200
0.01% 712
2024
Q1
$996K Sell
36,200
-1,300
-3% -$36.1K 0.02% 734
2023
Q4
$1.14M Sell
37,500
-7,500
-17% -$216K 0.02% 773
2023
Q3
$1.42M Sell
45,000
-15,000
-25% -$582K 0.02% 672
2023
Q2
$2.45M Hold
60,000
0.04% 447
2023
Q1
$2.24M Buy
60,000
+35,000
+140% +$1.37M 0.04% 420
2022
Q4
$872K Sell
25,000
-45,000
-64% -$2.14M 0.01% 794
2022
Q3
$3.92M Hold
70,000
0.05% 419
2022
Q2
$3.62M Sell
70,000
-42,500
-38% -$2.16M 0.05% 474
2022
Q1
$8.17M Buy
112,500
+75,200
+202% +$6.37M 0.1% 281
2021
Q4
$4.41M Sell
37,300
-80,200
-68% -$10M 0.05% 495
2021
Q3
$15.8M Sell
117,500
-386,600
-77% -$58.5M 0.18% 140
2021
Q2
$81.6M Buy
504,100
+294,800
+141% +$23M 1.07% 7
2021
Q1
$16.8M Buy
209,300
+109,300
+109% +$7.34M 0.36% 52
2020
Q4
$5.44M Buy
+100,000
New +$3.63M 0.12% 206

Other funds holding NTLA

Caption Management's NTLA Position: Q1 2026 in Review

Caption Management sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 20,000 shares — an estimated $255K sold.

Caption Management first reported a position in NTLA in Q1 2021 and held it in 15 quarters. The position peaked at $3.03M in Q1 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Caption Management reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 20,000 Intellia Therapeutics shares in Q1 2026, an estimated $255K.
  • Caption Management first reported a position in Intellia Therapeutics in Q1 2021 and held it in 15 quarters.
  • Caption Management's Intellia Therapeutics position peaked at $3.03M in Q1 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.